Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azithromycin/hydroxychloroquine - Iterum Therapeutics

Drug Profile

Azithromycin/hydroxychloroquine - Iterum Therapeutics

Alternative Names: Azithromycin plus hydroxychloroquine; Azithromycin/hydroxychloroquine

Latest Information Update: 09 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Iterum Therapeutics
  • Class Anti-inflammatories; Antibacterials; Antimalarials; Antivirals; Chlorobenzenes; Disease-modifying antirheumatics; Ethanolamines; Macrolides; Quinolines; Small molecules
  • Mechanism of Action Autophagy inhibitors; Phospholipase A2 inhibitors; Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Respiratory tract infections

Most Recent Events

  • 09 Sep 2021 Chemical structure information added
  • 07 Sep 2021 Iterum Therapeutics plans a phase III trial for Respiratory tract infections in USA (PO) in October 2021 (NCT05026801)
  • 07 Sep 2021 Iterum Therapeutics withdraws prior to initiation a phase III trial for Respiratory tract infections in USA (PO) in August 2021 due to inadequate support for the study(NCT05026801)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top